bioAffinity Technologies Inc. Receives Nasdaq Notice for Failing to Meet Listing Requirements

Reuters
31 May
bioAffinity Technologies Inc. Receives Nasdaq Notice for Failing to Meet Listing Requirements

bioAffinity Technologies Inc. $(BIAF)$ has announced that it received a notification from the Nasdaq Stock Market LLC regarding its non-compliance with Nasdaq Listing Rule 5550(b)(1). The company's stockholders' equity of $1,439,404 as of March 31, 2025, falls short of the required $2,500,000 for continued listing on the Nasdaq Capital Market. Despite this, bioAffinity Technologies' common stock will continue trading under the symbol "BIAF" while the company remains compliant with other listing requirements. A compliance plan is expected, and if not accepted, the company can request a hearing to delay any suspension or delisting actions. This notice is separate from a previous deficiency related to maintaining a minimum closing bid price of $1.00 per share.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-013021), on May 30, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10